Treatment for Spastic Diplegia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Spastic Diplegia+2 More
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial looks at how a surgery that cuts some nerves in the spine affects brain activity in kids with a certain kind of cerebral palsy.

Eligible Conditions
  • Spastic Diplegia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Baseline and 12 months

Baseline and 12 months
Change in Axial Diffusivity as assessed by brain MRI with diffusion tractography imaging (DTI) sequences
Change in Fractional Anisotropy as assessed by brain MRI with diffusion tractography imaging (DTI) sequences
Change in Mean Diffusivity as assessed by brain MRI with diffusion tractography imaging (DTI) sequences
Change in Radial Diffusivity as assessed by brain MRI with diffusion tractography imaging (DTI) sequences

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

15 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and 12 months

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
799 Previous Clinical Trials
250,044 Total Patients Enrolled
Manish N Shah, MDPrincipal InvestigatorUTHealth Medical School

Eligibility Criteria

Age < 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.